@Techinvestor
re "I can only go on the announcement of the "reduced" trial numbers made in Jan 16 where MSB clearly stated that they had agreed to a "second confirmatory study ... conducted in parallel in an identical patient population of approximately 600 subjects"."
As I recall the reduction in trial size to 600 was a reflection of the fact that the endpoint was changed to be recurrent HF-MACE which then allowed for the same patient contributing multiple events to the resultant data. So "more people/single event per person" became "less people/multiple events per person".
One thing I never quite understood in the discussion of multiple events is how they control for treatment after someone has an event. In other words, after a patient has an event, won't the treatment they receive compromise the data gathered? For example, if a patient does not have another event, how do they know this desired outcome was not due to the intervening (non msb) treatment they received, as opposed to the MPC-150?
I suppose they might be hoping all the events occur in the controlled group, and the MPC-150 group has no issues at all. However that might be a bit of a long-shot, because we know some of the phase 2 patients in the MPC-150 group required treatment over the 36 months, the number was only zero after the definition of HF-MACE was introduced.
- Forums
- ASX - By Stock
- MSB
- Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment
Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment, page-34
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
95.0¢ |
Change
-0.045(4.52%) |
Mkt cap ! $1.084B |
Open | High | Low | Value | Volume |
$1.00 | $1.01 | 94.5¢ | $2.669M | 2.769M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2053 | 95.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
95.5¢ | 13191 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2053 | 0.950 |
5 | 69192 | 0.945 |
16 | 152239 | 0.940 |
10 | 194253 | 0.935 |
9 | 112676 | 0.930 |
Price($) | Vol. | No. |
---|---|---|
0.955 | 13191 | 2 |
0.960 | 60726 | 4 |
0.965 | 33726 | 1 |
0.970 | 53885 | 3 |
0.975 | 54219 | 6 |
Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online